Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)

October 19, 2023

Endeavor Biomedicines doses first patient in phase 2 clinical trial of Taladegib (ENV-101) for idiopathic pulmonary fibrosis; appoints chief medical officer

September 22, 2021